Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.…
Arcutis Biotherapeutics (ARQT) Stock Looks Expensive Despite Its Huge Three Year Run
Arcutis Biotherapeutics (NASDAQ: ARQT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 354 employees.
The shares were at 26.36 USD on 20 November 2026, up 8.8% over 52 weeks. Its 52-week range is 19.30 USD to 34.80 USD: the price is 24.3% below the high and 36.6% above the low.
At a market capitalisation of 3.33B USD, it trades at 119.8 times trailing earnings and 24.1 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a premium of 262% for ARQT.
Arcutis Biotherapeutics reports return on equity of -8.5%, an operating margin of 6.9% and revenue up 45.1% year over year.
It holds more cash than debt, a net cash position of 135.64M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 8 analysts cover the stock, with an average rating of Buy; their mean price target of 40.38 USD is 53.2% above the current price. The next earnings report is expected on 24 February 2027.